AZP2006, a new promising treatment for Alzheimer's and related diseases.
Ontology highlight
ABSTRACT: Progranulin (PGRN) is a protein with multiple functions including the regulation of neuroinflammation, neuronal survival, neurite and synapsis growth. Although the mechanisms of action of PGRN are currently unknown, its potential therapeutic application in treating neurodegenerative diseases is huge. Thus, strategies to increase PGRN levels in patients could provide an effective treatment. In the present study, we investigated the effects of AZP2006, a lysotropic molecule now in phase 2a clinical trial in Progressive Supranuclear Palsy patients, for its ability to increase PGRN level and promote neuroprotection. We showed for the first time the in vitro and in vivo neuroprotective effects of AZP2006 in neurons injured with Aβ1-42 and in two different pathological animal models o
SUBMITTER: Callizot N
PROVIDER: S-EPMC8376949 | biostudies-literature | 2021 Aug
REPOSITORIES: biostudies-literature
ACCESS DATA